Trials / Terminated
TerminatedNCT02767752
Gemcitabine and Capecitabine With or Without T-ChOS as Adjuvant Therapy for Patients With Resected Pancreatic Cancer
A Single Center, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Gemcitabine (GEM) and Capecitabine (CAP) With or Without T-ChOS as Adjuvant Therapy in Patients With Surgically Resected Pancreatic Cancer.
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Herlev Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single center, randomized, double-blind, placebo-controlled phase II trial that will compare the efficacy of T-ChOS in combination with gemcitabine to gemcitabine alone as adjuvant treatment for 6 months in patients with surgically resected pancreatic adenocarcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | T-ChOS | |
| DRUG | Gemcitabine | |
| DIETARY_SUPPLEMENT | Placebo | |
| DRUG | Capecitabine |
Timeline
- Start date
- 2016-11-01
- Primary completion
- 2018-07-01
- Completion
- 2018-07-01
- First posted
- 2016-05-10
- Last updated
- 2018-07-10
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT02767752. Inclusion in this directory is not an endorsement.